Literature DB >> 10764150

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.

P E Hoyle1, P W Moye, L S Steelman, W L Blalock, R A Franklin, M Pearce, H Cherwinski, E Bosch, M McMahon, J A McCubrey.   

Abstract

In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activities conditionally dependent upon exogenous beta-estradiol. The vast majority of deltaRaf:ER-infected FDC-P1 cells remained cytokine-dependent; however, cells were obtained at low frequency in which expression of deltaRaf:ER abrogated cytokine dependency. Isoform specific differences between the Raf kinases were observed as cytokine-independent cells were obtained more frequently from deltaA-Raf:ER than either deltaRaf-1:ER or deltaB-Raf:ER infected cells. To determine whether the regulatory phosphorylation sites in the Raf proteins were necessary for abrogation of cytokine dependency, they were changed by site-directed mutagenesis. Substitution with phenylalanine eliminated the transforming ability of the deltaB-Raf:ER and deltaRaf-1:ER kinases. However, a similar substitution in A-Raf did not extinguish its transforming activity. The activated Raf proteins induced essential downstream MEK1 activity as treatment with the MEK1 inhibitor, PD98059, suppressed Raf-mediated growth. Activated MAP kinases (ERK1 and ERK2) were detected in deltaRaf:ER-transformed cells, and their presence was dependent upon a functional MEK1 protein. The cytokine-independent phenotype required the continued activity of the deltaRaf:ER proteins as removal of beta-estradiol caused the cells to stop growing and undergo apoptosis. The Raf-responsive cells were found to express autocrine growth factors, which promoted their growth. Constitutive activation of the Raf-1 oncogene resulted in malignant transformation as cytokine-independent FDC-P1 cells infected with a retrovirus encoding an activated Raf-1 protein formed tumors upon injection of immunocompromised mice. In summary, Raf kinases can abrogate cytokine dependency, prevent apoptosis and induce the tumorigenicity of a certain subpopulation of FDC-P1 cells by a MEK1-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764150     DOI: 10.1038/sj.leu.2401720

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.

Authors:  David Wan-Cheng Li; Jin-Ping Liu; Ying-Wei Mao; Hua Xiang; Juan Wang; Wei-Ya Ma; Zigang Dong; Helen M Pike; Rhoderick E Brown; John C Reed
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

Review 3.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 4.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

5.  Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Khalief E Hamden; Patrick W Ford; Audy G Whitman; Ossie F Dyson; Shi-Yuan Cheng; James A McCubrey; Shaw M Akula
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.

Authors:  Mohammad Faraz Naqvi; Henry Hiep Vo; David Vining; Apostolia-Maria Tsimberidou
Journal:  Ther Adv Med Oncol       Date:  2021-03-24       Impact factor: 8.168

7.  LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Authors:  MyLinh T Duong; Said Akli; Caimiao Wei; Hannah F Wingate; Wenbin Liu; Yiling Lu; Min Yi; Gordon B Mills; Kelly K Hunt; Khandan Keyomarsi
Journal:  PLoS Genet       Date:  2012-03-29       Impact factor: 5.917

8.  A Clinical Evaluation of Circulating MiR-106a and Raf-1 as Breast Cancer Diagnostic and Prognostic Markers.

Authors:  Elham Ahmed Mohmmed; Wafaa Ghoneim Shousha; Abeer Salah El-Saiid; Shimaa Shawki Ramadan
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

Review 9.  Conferring specificity on the ubiquitous Raf/MEK signalling pathway.

Authors:  E O'Neill; W Kolch
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  The role of slingshot-1L (SSH1L) in the differentiation of human bone marrow mesenchymal stem cells into cardiomyocyte-like cells.

Authors:  Jian-Wu Zhao; Mu-Rui Zhang; Qiu-Ye Ji; Feng-Juan Xing; Ling-Jie Meng; Yan Wang
Journal:  Molecules       Date:  2012-12-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.